This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Stock Market News for Nov 18, 2024
by Zacks Equity Research
Wall Street continues its decline on Friday following the Fed Chairman???s hawkish statement on rate cut.
Trump Taps RFK for HHS: Time to Avoid Biotech?
by Andrew Rocco
With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers. Stock Strategist Andrew Rocco explains.
Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS
by Sundeep Ganoria
President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
by Zacks Equity Research
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
Initial Claims Increased Slightly More Than Expected
by Zacks Equity Research
Initial Claims Increased Slightly More Than Expected
Ahead of Fed Decision, Big Earnings Wins for Forgotten Names
by Mark Vickery
The long-expected big news item for market participants this afternoon is the Fed interest rate move.
Moderna (MRNA) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 101.59% and 47.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
by Kinjel Shah
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Moderna (MRNA) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Moderna (MRNA) Stock Moves -0.66%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) concluded the recent trading session at $54.36, signifying a -0.66% move from its prior day's close.
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Moderna (MRNA) closed at $55.22, indicating a +0.77% shift from the previous trading day.
Company News for Oct 29, 2024
by Zacks Equity Research
Companies In The Article Are:BA, TSM,MRNA, ON
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
by Zacks Equity Research
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
Why Moderna (MRNA) Dipped More Than Broader Market Today
by Zacks Equity Research
Moderna (MRNA) reachead $53.80 at the closing of the latest trading day, reflecting a -0.55% change compared to its last close.
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
by Kinjel Shah
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
by Zacks Equity Research
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.